Eli Lilly and Company (LLY)
Why Eli Lilly Stock Popped Today
Eli Lilly (LLY 2.10%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases.
Eli Lilly introduces new doses of weight loss drug Zepbound at discounted prices
Eli Lilly and Co (NYSE:LLY) has announced a reduction in the price of its weight-loss medication Zepbound for patients who pay for the drug out of pocket. The company is now offering higher-dose 5mg vials of Zepbound at a discounted rate of $499 per month, a $150 decrease from the previous price of $649 for the auto-injector pen versions.
Eli Lilly: Load Up Before It Leaves You Behind
Eli Lilly investors have been "quietly" loading up, as the stock outperformed the S&P 500. Lilly has been making gains against Novo Nordisk, and the advance may not be over. Policy risks and pricing changes could be risks to consider later, but the stock is still assessed to be undervalued when we consider LLY's PEG ratio.
Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.
Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Lilly launches higher dose vials of weight-loss drug for $150 less than injector pen
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine.
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage for the blockbuster injection, such as those with Medicare. The company is offering those vials through its direct-to-consumer website, LillyDirect, which started offering lower doses of the drug in vials in August.
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Don't Overlook Lilly (LLY) International Revenue Trends While Assessing the Stock
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Lilly's Chief Scientific Officer: 'We have an obligation to go after big problems'
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
